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Abstract
Background: The aim of this study is to assess and evaluate the capacities for understanding,
appreciation and reasoning of legal minors with psychiatric disorders and their parents and their
competence to consent or assent to participation in clinical trials. The beliefs, fears, motivation and
influencing factors for decision-making of legal minors and parents were also examined.
Methods: Using the MacArthur Competence Assessment Tool for Clinical Research (MacCAT-
CR), an instrument developed for adults whose capacities to consent are unclear, we provided
information about clinical trials and assessed understanding, appreciation and reasoning. We
adapted this tool for legal minors and examined 19 children and adolescents between the ages of
7 and 15 with attention deficit/hyperactivity disorder (ADHD) or ADHD combined with
oppositional defiant disorder (DSM-IV 314.00/314.01/312.8) enrolled in clinical trials. Parents were
also examined using the MacCAT-CR.
Results: Facts such as the procedures involved in trials or their duration were well understood by
legal minors, but more abstract issues like the primary purpose of the trial were not understood
by children and adolescents or by many parents. Legal minors also had difficulties understanding
the nature of placebo and the probability of receiving placebo. Children's and adolescents' decisions
were influenced by fears about their disorder worsening and by problems in their relationship with
their parents. Parents wanted the best therapy for their children in order to minimize problems in
school.
Conclusion: Legal minors and parents need to be informed more precisely about specific issues
like placebo and the primary purpose of trials. In general, the reasoning of children and adolescents
was influenced by their experience with their disorder and decision making was based on
reasonable arguments. Their fears were based on everyday experiences such as school
performance or family relationships.
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Background
The involvement of children and adolescents in the deci-
sion-making process is an ethical prerequisite if they are
asked to participate in clinical trials [1]. Although children
and adolescents under 18 years in Germany (and in most
countries) are legal minors and do not have the "legal
capacity to consent" to research [2], children and adoles-
cents have the right to information about research and to
participate in the decision-making process, which is not
necessarily connected to their competence to give legal
consent [1,3,4]. The participation of legal minors is
required and guaranteed by several guidelines, ethical
codices and the law, even if choices patients make may be
irrational, idiosyncratic, or unreasonable. It is a process of
balancing the children's rights to decision making with
their ability to deal with the responsibilities that come
with it and with the responsibilities of parents for the
decision making of their child [5]. Theoretical discussions
about aspects of consent, assent and participation of legal
minors and about the validity and conceptualisation of
assent continue [6-8]. As psychopharmaceutical interven-
tions have increased in recent years and clinical trials are
more frequently conducted in the area of child and ado-
lescent psychiatry [9], information for children and ado-
lescents and their participation in the decision-making
process will be a basic ethical need in the future. The ques-
tion remains, how much do children and parents under-
stand of the information provided about clinical trials in
child and adolescent psychiatry and what is the best way
to guarantee that the children's assent is meaningful?
Some studies have examined the capacities of parents in
cases where their children participated in clinical trials e.g.
in anaesthesia, oncology or surgery [10-15]. The results
indicated that some parents had a high level of under-
standing of the study or treatment procedures, although a
high proportion of parents showed no understanding of
the risks and of the research nature of the clinical trials.
Randomization, in particular, was not well understood.
Research on the participation of legal minors in the med-
ical context is limited, but the few studies that do exist
reveal that minors have well developed competences with
regard to decision making in concrete treatment situations
[16], that competences depend on the developmental sta-
tus of the children and adolescents [17] and that confi-
dentiality is important for young patients [7]. Most of
these studies were conducted with somatically ill patients
and few data are available in paediatric psychiatric
patients. It could be assumed that psychiatric disorders
influence subjects' capacities and competences in particu-
lar [18] and competences of children can change over
time depending on developmental status. Furthermore, in
some child and adolescent psychiatric disorders, concep-
tualization of the disorder by both parents and children
may affect the reasoning of parents or children in decision
making about treatment strategies or joining a clinical
trial.
Abramovitch et al. [19] examined the capacity of children
between the ages of 5 and 12 to consent to psychological
research and concluded that, in general, children of these
ages do have the capacity for meaningful assent to partic-
ipation in research. Most of the children understood all or
most of what they were asked to do in a psychological
study, but few children below the age of 12 fully under-
stood or believed that their performance would be confi-
dential. Moreover, many children of all ages believed that
there would be some negative consequences if they asked
to stop. But this finding was inconsistent with the results
obtained by Tait et al. [17] in children in surgical research.
These children were not unhappy about annoying their
doctors if they left the study.
Several authors observed a strong desire in children and
adolescents to participate in the information and deci-
sion-making process on medical procedures, including
standard medical care, even if the legal minors were una-
ble to decide for themselves [20,21]. Children with psy-
chiatric disorders or mental illnesses also wanted to be
involved in the decision-making process [22-24]. There
are two parts to participation: one refers to information
(about the medical treatment/research project/clinical
trial), which can increase the feeling of being involved
[25-27]. The second aspect refers to the decision making
itself (being involved in decision making/was the opinion
of the children and adolescents respected?), which is
reflected in whether or not the decision of the child or
adolescent was accepted by parents and physicians [8,24].
But empirical data indicate that this is exactly where the
deficiencies lie, namely in the information practices and
involvement in the decision-making process, particularly
of younger children [24,28].
As the competences of children and adolescents depend
on the severity of their disorder, their developmental stage
and other associated factors, these competences and fac-
tors have to be empirically examined. Which factors and
arguments influence a child or adolescent suffering from
paediatric and adolescent psychiatric disorders to assent
or to refuse participation in a clinical trial? The most com-
mon disorders in child and adolescent psychiatry are
attention deficit/hyperactivity disorder (ADHD) and
oppositional defiant disorder (ODD). ADHD is character-
ized by impulsivity and inattention. The main characteris-
tic of ODD is noncompliance with the instructions of
adults. Both disorders may influence the decision making
of children and adolescents and both disorders are com-
monly treated with psychopharmacological interven-
tions. Therefore we wanted to examine whether it wouldChild and Adolescent Psychiatry and Mental Health 2009, 3:2 http://www.capmh.com/content/3/1/2
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be feasible to use an instrument developed for adults
whose capacities and competences are unclear, and
whether this would help to improve informing legal
minors about studies in which they are asked to partici-
pate. In our study on children and adolescents with
ADHD and/or ODD and their parents, we examined both
the feasibility of providing information about clinical tri-
als according to informed consent criteria and the under-
standing of information related to clinical trials. The
appreciation of children and adolescents and their parents
of what a clinical trial involved and their reasoning about
participation in a clinical trial were examined. Further-
more, we analysed their attitude to health and their hopes
and fears in relation to their disorders and their therapies.
We wanted to shed light on the kind of arguments used by
children and adolescents to give their assent or to refuse to
participate in a clinical trial with medication. In addition,
we examined the beliefs of parents about the necessity,
advantages and risks of their child's participation in a clin-
ical trial. To inform children and parents and to assess
competences we used the MacArthur Competence Assess-
ment Tool for Clinical Research (MacCAT-CR) [29,30].
Methods
Instrument
The MacArthur Competence Assessment Tool for Clinical
Research (MacCAT-CR) is one of the standard interna-
tional tools for the assessment and evaluation of compe-
tences for consent [29,31]. Both the MacCAT-CR and a
similar instrument for treatment decisions, the MacArthur
Competence Assessment Tool for Treatment (MacCAT-T),
have been used in different studies in adults to evaluate
capacities for decision making [32-38]. The MacCAT-CR is
a semi-structured interview which relies on international
criteria for informed consent (see also [30]). The MacCAT-
CR is used to disclose relevant information to patients
about their illness, treatment options in the study, and the
risks and benefits of those options. The understanding,
appreciation and reasoning of patients is evaluated in sev-
eral parts and subparts. Participants are encouraged to
explain the contents they have understood. The MacCAT-
CR was adapted for children and adolescents using age-
related terms and explanations. Interviews take about 35–
60 minutes, depending on the need to repeat questions
and the nature of the answers given by the participants.
Interviews were conducted with the children and adoles-
cents and their parents. The children and adolescents and
their parents were interviewed separately. The feasibility
of applying the MacCAT-CR in legal minors and scoring
according to MacCAT-CR guidelines are reported else-
where [30]. Whereas this instrument is mainly used to
assess the capacity to consent in vulnerable populations,
we used the MacCAT-CR as a tool to provide information
and to assess and analyze the beliefs, motivation and fears
of children and adolescents and their parents about par-
ticipation in a clinical trial (see table 1). The complete
interviews with the children and adolescents and parents
were used for the analyses, independently of whether the
answers given by the children, adolescents or parents were
in line with informed consent criteria. The MacCAT-CR
scores [30] were used to identify the answers which did
not correspond to informed consent criteria as well as
those that did. Both the corresponding and non-corre-
sponding answers were analysed to illustrate the beliefs
and motivations behind the formal criteria of informed
consent.
Participants
Two groups of children and adolescents were interviewed
(19 children and adolescents in total). One group had
attention deficit hyperactivity disorder (ADHD) alone
and the other ADHD combined with oppositional defi-
ant-disorder (ODD). Diagnoses were verified during
examinations conducted at enrolment into the clinical
medication trials (see below, K-SADS, SNAP were used
among others) and diagnoses were made according to
DSM-IV. For sample characteristics see table 2.
The ADHD + ODD group was asked to join a randomized
placebo-controlled trial in which an investigational drug
(atomoxetine) was administered to treat the two disor-
ders. Atomoxetine was not licensed in Germany at the
time of the study. The children and adolescents with
ADHD only were asked to join an open-label trial
(licensed drug) using a long-acting methylphenidate
preparation. 17 of the 19 children and adolescents had an
average intelligence level (IQ 85–115, see table 2). None
of the children or adolescents had experience with the
study medication; nine children and adolescents were
medicated with methylphenidate at the time of the inter-
view and thirteen had prior experience with different
types of psychotherapeutic medications.
19 parents were interviewed. Parents belonged to all
social strata, which were classified using the standard clin-
ical documentation (basic documentation of the German
Society for Child and Adolescent Psychiatry and Psycho-
therapy) into low, average and high social status by
employment (see table 2).
Interviewers
The interviews were conducted by the clinical trial investi-
gators (N = 3). One of the interviewers worked as a child
and adolescent psychiatrist, and two of the interviewers
were physicians in training for child and adolescent psy-
chiatry. The interviewers were trained in conducting these
interviews.Child and Adolescent Psychiatry and Mental Health 2009, 3:2 http://www.capmh.com/content/3/1/2
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Analysis
Each interview was audiotaped and transcribed. Inter-
views were independently analysed by two psychologists,
who were not conducting the interviews. Both analysers
were trained in assessing the interview.
Another analysis was done by rating the interviews but
these results are reported elsewhere [30]. The attitudes of
children and adolescents and parents towards health and
their concept of clinical trials were investigated. The
answers were analysed using qualitative methods to gain
insight into the decision-making process of children and
adolescents. Analysis was conducted in a similar way to
qualitative content analysis [39,40], but some modifica-
tion was necessary as categories of contents were already
provided by the MacCAT-CR (see table 1). First we
searched for parts which were not well understood by the
participants. Then answers were searched for the
sequences, in which children and adolescents and parents
explained their decision making and the rationale for
their decision. Analysis was not restricted to explanations
that were in line with informed consent criteria.
Table 1: sections and subparts of MacCAT-CR
Understanding
Disclosure: nature of project
Disclosure: primary purpose is research
Disclosure: effect of research on individualized care (e.g. placebo, randomized design)
Disclosure: risk/discomfort (side-effects)
Disclosure: ability to withdraw
Appreciation
primary purpose is not individualized care
An explanation was e.g.:
"The doctors can explore whether the new medication works well in patients with an ADHD."
Reasonable possibility of less personal benefit (e.g. placebo)
Questions were e.g.:
"Are all the children in this study given the new medication?"
"Do you think you will receive a sugar-pill, a tablet without any agent?"
believes that the decision to withdraw will be honoured
Reasoning
consequential and comparing reasoning
"Well, what is your decision now?"
Generation consequences (e.g. on every day life)
In case of assent: "why have you made this decision, what are the reasons for your decision?" "OK. You say you want to take part. Why did you 
decide to take part? What were your reasons?"
logical consistency
Expressing a choice
Expressing a choiceChild and Adolescent Psychiatry and Mental Health 2009, 3:2 http://www.capmh.com/content/3/1/2
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Results
In our study, the parents in particular showed a strong
desire to speak during the informational conversation
about their child's problems, the patient's history and
former therapeutic interventions which were effective or
which failed. Furthermore, parents were interested in
speaking about the present impact of the disorder on their
child's ability to function in every daily life.
Children and adolescents were asked whether they were
content with the interview. They were interested in talking
about the study, but all of the 19 participants were bored
and annoyed by being repeatedly asked the same ques-
tions, as is required by the MacCAT-CR for evaluating
capacities.
After the interview, 10 children and adolescents from the
group with combined ADHD and ODD assented to their
participation in the study. In the group with ADHD only,
5 minors gave assent, one minor refused and one was
undecided. 18 of the 19 parents interviewed consented.
Understanding
Altogether, 10 of 19 of the children and adolescents were
able to understand the information about the trial very
well, 7 of 19 understood the information at a large extent
but showed some deficiencies in understanding and only
2 of 19 children had a completely insufficient understand-
ing. Issues which were very well understood or which were
not well understood by the participants are described fol-
lowing more detailed. Except the named two participants,
the children and adolescents showed sound understand-
ing of study procedures such as study visits, duration of
the trial, blood drawing, being sober and taking medica-
tion etc. The same 17 of the 19 children also had a very
precise understanding of possible side-effects. But most of
the children (n = 13) failed to understand that the primary
objective of the clinical trial was research and not the best
individualized care and personal benefits. Even parents
did not perform well in understanding this fact.
In addition, in the placebo-controlled clinical trial, the
nature of placebo and randomization seemed to be too
complex for the children and adolescents to understand.
This part was not well understood by two thirds of the
children and adolescents and even a small minority of the
parents. Whereas children and adolescents understood
the term "sugar-pill", the significance and nature of the
placebo was not understood. Furthermore, children and
adolescents underestimated the possibility of receiving
placebo. Most, but not all (16 of 18), parents understood
the nature of placebo although half of the parents did not
comprehend the significance of randomization.
Both parents and children and adolescents clearly under-
stood that they were not forced by physicians to partici-
pate and that they could terminate participation at any
time. The two children with a sub-average IQ performed
more poorly than the other children in understanding,
and also in all further sections of the MacCAT-CR (see also
[30]).
Appreciation
Especially in the part of the MacCAT-CR where "apprecia-
tion" was evaluated, children and adolescents performed
inappropriately to criteria as required by the MacCAT-CR.
A basic element of informed consent or assent is a sub-
ject's appreciation that he or she is asked to participate in
a study for the purposes of research, and not to receive the
best individual care. MacCAT-CR tests this appreciation by
asking the participants why they think that they have been
asked to participate in the clinical trial. Children under-
stood that the efficacy of a medication has to be tested, but
there were misconceptions about why efficacy has to be
tested, which were not directly correlated with the age of
the children. 16 of the 19 children thought that the trial
would examine whether the medication would help
them:
"So that I feel better and just generally."
Table 2: Sample characteristics
Study type Diagnosis DSM-VI Social status of the 
parents
N minors Sex Age Mean (SD) IQ Mean (SD)
Open-label trial with an 
extended-release 
methylphenidate 
preparation for ADHD
5 *314.01, 2 * 314.00, 2 
*concomitant 315.2, 1* 
concomitant 312.8
3 high
5 average
0 low
7 boys 13.3 (2.4) 104.1 (13.9)
Placebo-controlled RCT with 
a new SNRI-preparation for 
ADHD + ODD
12 * 314.01 + 312.8, 
1*concomitant 315.2
2 high
9 average
1 low
12 boys 9.9 (1.7) 97.2 (14.7)
Total
Range
19 11.0 (2.3)
7–15 y
99.8 (14.5)
72–132Child and Adolescent Psychiatry and Mental Health 2009, 3:2 http://www.capmh.com/content/3/1/2
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Boy P, 12 years old
"That it helps me (...) and whether it helps other kids."
Boy R, 10 years old
"Because if it (the medication) is not effective, and the medi-
cation is sold and the doctor in the pharmacy...ehm, if the med-
ication does not work then, then people buy it and then they
spend their money for nothing."
Boy S, 9 years old
For almost all children as well as for more than one third
of the parents, their appreciation of the primary objective
of the trial (which was research) was that they would
derive personal benefit by joining the trial. The fact that
the primary objective of the trial was research was not
really appreciated by the children. The children and ado-
lescents in particular did not consider that the aim of the
question was to make them think about the altruistic
aspect of research participation. It was not the participants
but the researchers who would primarily benefit by con-
ducting the trial, whereas the benefit to the patient was
questionable. Children thought they were asked to partic-
ipate in the trial because they would personally benefit
from this. They explained that, from their personal point
of view, they expected benefits for themselves. For exam-
ple, a handful of the children and adolescents said that the
personal benefit they expected from participation would
be that they were one of the first to receive a new treat-
ment or medication. They appreciated the new medica-
tion and believed it to be the best and most innovative
therapy.
One boy had a realistic attitude about the trial. He said
that many children were necessary because the effective-
ness of the medication was not proven. One boy answered
the question about what role he would play in the study
correctly:
"I think I will be something like a guinea pig."
Boy H, 12 years old
Therefore, he appreciated correctly that he would join a
trial where the primary purpose was research but he had a
misconception about why he was asked to join. The same
boy's answer to the question of what the primary objective
of the trial could be and why he was asked to participate
in the trial was:
"Because, I'm something like a special case, because I'm really
intelligent, I'm suffering from ADHD and at the same time
from ODD and I also have dyslexia and because of me being a
mixture of nearly everything (...)."
Boy H, 12 years old
Another boy, very young, offered altruistic reasons for
why he was asked to join the trial:
"And, that it will improve the disease in others, and that it (the
medication) also helps other children, because it should also
help other children, not only me."
Boy S, 8 years old
A mother expressed her appreciation of the primary objec-
tive of the trial in very realistic terms:
"We can benefit from it, you can benefit from it or we can all
or both go down the drain with it."
Mother of boy K (10 years old)
While appreciating the nature of placebo and the possibil-
ity of receiving placebo, participants shared with us their
personal beliefs about why they or their children received
placebo. They applied placebo to their own personal situ-
ation. For instance, one of the participants thought pla-
cebo was dispensed to prove whether he really suffered
from ADHD and was not pretending. No child appreci-
ated that there was a fifty/fifty chance of receiving placebo.
The perception of whether they would receive placebo or
not was driven by the children's beliefs, and not by a real-
istic balancing of the chances.
Interviewer: "Who decides whether you will receive a placebo?"
„The psychologist"
Interviewer: (...) "Do you think you will receive a placebo?"
"Not really"
Interviewer: "Why not"
"Ehm because, in fact, I don't know, I don't have a reason."
Boy S, 8 years old
In response to the question whether they thought they
might receive placebo, all the children and adolescents
believed they should first explain why a placebo is used in
a study. Their appreciation was that another child could
receive placebo, but not they themselves. One boy said
that he thought there was a placebo control in the trialChild and Adolescent Psychiatry and Mental Health 2009, 3:2 http://www.capmh.com/content/3/1/2
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and that nobody would know whether he received a pla-
cebo or not.
"ehm I will probably receive a sugar pill between visit two and
visit five, you won't know that, my mother won't know, and I
won't know either, and nobody else will know. And what might
happen is that I will be a little bit fidgety, that I will be fidgety
and, ehm, on visit five I will receive the true medication (...) (I
will receive the placebo) to explore, ehm, whether the new med-
ication, if this medication is superior, as if I take no medication,
or if I take the new medication."
Boy L, 10 years old
According to him, the purpose of placebo was to help clar-
ify whether the new drug would be superior to taking no
medication. This would appear to be correct, but he went
on to say that if he did receive placebo he could develop
some symptoms of ADHD and therefore he and the study
physicians could clarify whether he needed a medication
or not. He believed that the placebo would be given to
him to clarify whether it would be better for him to take
any medication or no medication.
Parents also had some difficulties with appreciating pla-
cebo. A mother thought that placebo would be given to
test whether the medication really worked for her son.
Another mother thought that placebo would help clarify
whether her son really suffered from the disorder or
whether he needed more attention from his family. This
mother's answer to the question of whether she believed
that her child could get a placebo was as follows:
"Perhaps, I imagine that what will be tested is if he needs it (the
medication) or if he really just (needs) attention!"
Mother of boy H (12 years old)
The MacCAT-CR stresses possible misconceptions by
patients who think they will not receive any treatment if
they refuse to participate in the study, or that the physi-
cian will be angry or that this decision would harm the
physician-patient relationship. According to MacCAT-CR,
competent appreciation means understanding that the
consequence of refusing participation will lead to the
patient's receiving another treatment. One boy's answer
about the consequences of refusing participation, which
was typical for half of the children, was:
"If I do not want to join from the beginning, then Dr. XY
(former therapist) continues to care for me, and then, if I want
to participate, you will treat me, but I do not have to partici-
pate."
Boy K, 10 years old
In our study, the children and adolescents were troubled
or thought that their disorder was becoming worse and as
a consequence that they would perform worse in school
or would have problems with their parents if their oppo-
sitional defiant disorder symptoms became worse. Many
of the children and adolescents had prior experience with
medication or psychotherapy and the effects of this med-
ication/psychotherapy were often unsatisfactory or disap-
pointing. Therefore, it is understandable that they did not
refer to the alternatives represented by medication or psy-
chotherapy. However, it is impossible to rule out that
some children and adolescents thought that the only
available medication would be the study medication.
Whereas it was very difficult for children and adolescents
to deliberate on the primary objective of the trial, they
were able to appreciate fully the benefits, risks and conse-
quences for every day life. Neither children and adoles-
cents nor parents thought that a potential decision on
their part to refuse to take part in the trial would have neg-
ative consequences on the relationship between them-
selves and their physicians or on any further treatment in
the department.
Reasoning
All children and adolescents indicated that the reasons
why they decided to participate were that they wanted
help with the problems related to their disorder: problems
in school, problems with friends and with their families.
Children and adolescents argued that if they did not par-
ticipate, they would worry about performing worse in
school and would experience problems with their parents
and families because of behavioural problems. One boy
indicated that he would participate because otherwise he
feared he could become more aggressive and hurt his
mother. His reason for deciding to participate was that he
wanted to improve and change his disruptive behaviour.
He thought his behaviour was not fully under the control
of his own will, which was a view also expressed by about
half of the 19 children:
"Then it will get worse (with my symptoms), or well I think that
it will get worse, because it got worse every year, ehm, I will
grow up, will be stronger, and then puberty will come as well,
so I think, I should participate, well for my mother's sake and
even for my sake."
Boy H, 12 years old
Other boys made the following statements:
"Because I believe, I believe that with the new medication eve-
rything will be much better (...) I just have faith in the new
medication."Child and Adolescent Psychiatry and Mental Health 2009, 3:2 http://www.capmh.com/content/3/1/2
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Boy L, 10 years old
"I will just take it, I'll go along. I will just try it and see how it
goes. (...)Well, so I can see how it will work and so on and if I
will be able to concentrate a bit then."
Boy K, 10 years old
"Yes, because I am interested to see if it helps me."
Boy B, 10 years old
Children with ADHD combined with an ODD did not dif-
fer from those without an ODD in their hopes that study
participation, or the study medication, would help them
to reduce problems in their families and with peers. In this
sample, the ODD did not lead to more conflictual rela-
tionships with parents on the issue of study participation
and therefore children with an ODD were no less willing
to participate.
Both parents and children indicated their high expecta-
tions of the effectiveness of the new medication and their
decision to join the trial were driven by fears of antici-
pated problems in school and at home if they did not try
a new (and supposedly better) therapy. The failure of
prior therapeutic interventions was the main reason for
parents to decide that the child should participate in the
trial. A mother made this statement:
"Well, we're not happy with the effects of previous therapies,
there are problems in school, and we want to help him with the
best option. Therefore we see this (participation in the trial) as
a way of doing this."
Mother of boy U (8 years old)
"I hope that the study will bring some positive effects for (my
son) and we can optimize the therapy."
Mother of boy F (11 years old)
As one perceived advantage of the study medication was
the fact that methylphenidate was supplied in an
extended-release formulation, six of seven parents and
three of seven children and adolescents incorporated this
expected advantage into their reasoning. The hope that
the medication would be more effective because of the
element of constant release was indicated as one reason
influencing their decision. Furthermore, the fact that the
new medication was easier to handle, in that it had to be
taken only once a day and not twice or three times daily
as was the case with the licensed preparations for ADHD,
was seen as an advantage and a reason for participation.
Six of seven parents, as well as 3 of the 7 children and ado-
lescents asked to use a long-acting methylphenidate prep-
aration, recognized that the once-a-day dosing decreased
the risk of forgetting to take the medication and was a very
important advantage as it made it possible for the children
and adolescents not to have to take the medication in
public (e.g. in school). Therefore, children and parents
thought that once-a-day dosing removed the stigma asso-
ciated with having to take the licensed preparation in pub-
lic.
"One reason for me is definitely that I can forget it (the regular,
not extended-release methylphenidate) and on the other hand I
am a little bit interested in it and how it will be then (the
extended-release methylphenidate)."
Boy G, 15 years old
Further advantages were seen in the hope (or therapeutic
misconception) that participation in a research trial
would supply the children and adolescents with the best
and most innovative medication, which would not be
available elsewhere. In 10 of the 19 cases, the decision was
driven by the failed efficacy of previous medications.
Side effects were not always anticipated to be very negative
by children and adolescents. Two boys stated that there
were benefits from suffering mild side effects such as
bellyaches or nausea: they would not have to go to school.
One very young boy estimated that the side effects would
not bother him very much:
"I may get stomach troubles, but never mind."
Boy T, 8 years old
Blood drawings and examinations were expected to be
disliked and one boy argued that he was afraid to have his
blood drawn and therefore did not assent to participate.
"I don't want to join. (Why?) Due to the blood drawing, (...),
yes, this would be the worst for me. "
Boy U, 8 years old
When children or adolescents participated in trials, a dif-
ferent physician from the research unit cared for them and
they no longer saw the one who had previously given
them routine care. Therefore, one child was afraid of los-
ing his therapist with whom he had a good therapeutic
relationship. More than half of the children and adoles-
cents felt bothered by the need to make frequent visits to
the study physician for the purposes of study examina-
tions. The large amount of time needed to participate in
the study was weighed up by the children and adolescents.Child and Adolescent Psychiatry and Mental Health 2009, 3:2 http://www.capmh.com/content/3/1/2
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The children who did not assent found the balance to be
negative:
"I do not want to participate, because I want to continue with
my group (therapy), there I know many of the other kids, and
here I know nobody, (...) there all my friends go to the group.
There (in the group therapy) my other friends also attend, from
my school, my friends from my previous school attend. And even
if the group ends now, we can still go there in the future. (...)
Also, my old medication did work a little bit and improved me.
My leisure activities would be worse, if I had a visit on Friday
or Tuesday, that's when I always have handball training, all
day, and Thursday, that's when my grandmother comes to us,
therefore I cannot come to the department, and on Wednes-
days, then my aunt comes to see me. My aunt and sometimes
my cousin or it is a family evening or something like that. (...)
I can't quit handball and I can't miss seeing my grandma, I
can't."
Boy S, 8 years old
The children and adolescent who assented considered the
time that participation would involve but were able to
balance it out with the expected benefits.
"Well, I do have a lot to do but I would fit it in."
Boy E, 13 years old
10 of the 19 parents stated that one disadvantage of the
clinical trial was the large amount of time involved. For
example, they mentioned difficulties such as long car
journeys to the clinic, less leisure time or less time for
sports activities for the child. When parents refused to
allow their child to participate in the study, the reasons for
refusing included that it was too great a commitment
(above all in terms of time) and fear of giving an investi-
gational drug to the child over a long period of time.
Although they gave their consent to participation in the
study, other parents and children also stated that they had
concerns about participation. Overall, the main fear about
joining clinical trials was the fact that their child would
receive an investigational drug over a long period of time.
One mother indicated fears that the new medication
might deliver a higher dosage than needed – which was
indeed the case. As the study medication was adminis-
tered at fixed doses, a higher dosage per kilogram body
weight was prescribed.
Two third of the children and almost all parents did not
think that refusal to participate could bring negative con-
sequences on the level of health care or personal depend-
ence on the physicians. They reasoned that personal
negative consequences would be in terms of poor school
achievements, arguments with their parents etc. But none
of the children or parents expected negative consequences
in the health care setting or in their personal relationship
to their doctors. This may be related to the German health
care system, where access to care and availability of medi-
cation, psychotherapy and child and adolescent care is
almost entirely guaranteed.
This study identified some categories of arguments and
considerations on the part of the children that induced
them to participate in a study or to refuse participation
(Table 3). Hope that their symptoms and, in somewhat
more abstract terms, their behaviour would improve were
aspects which motivated children and adolescents to
assent. Both the personal benefits of improved symptoms
(e.g. better concentration in school, fewer arguments with
peers) as well as the benefits for their parents and families
were considered by children. Furthermore, the expecta-
tion of a more user-friendly medication taken no more
than once a day was a reason for children and adolescents
to assent and to undergo the examinations of a clinical
trial. The chance to test something new represented a third
group of reasons which motivated children to assent.
Most of the children wanted to test the new medication to
see whether it would work for them. This could be
Table 3: Motivating and discouraging factors for children to participate in clinical trials
Motivating factors
- Hopes for improvement of their own behaviour based on experience
With benefit for themselves
With benefit for their families
- Comfort (once a day vs. several times a day)
- Explorative behaviour/sensation seeking
Discouraging factors
- Changes in treatment settings
- Time spent
- Study examinations, especially invasive exams/blood-drawingChild and Adolescent Psychiatry and Mental Health 2009, 3:2 http://www.capmh.com/content/3/1/2
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regarded as a sort of sensation-seeking behaviour or a type
of explorative behaviour, but it also indicated their expe-
rience of treatment failures in the personal history of their
disorder. They balanced the option of being the first to test
a new and maybe better medication against the risks and
decided for participation in the trial, although the chil-
dren also appreciated the disadvantages and the risks of
the trial.
Factors which influenced children to refuse assent to par-
ticipation included changes in their treatment settings
with new physicians and loss of their familiar therapists
and peers from their group therapy. Furthermore, the high
amount of time spent on frequent visits to the hospital
was a reason which discouraged assent. The third category
of reasons for not assenting were the study examinations,
especially invasive medical procedures such as blood
drawing which can be expected to scare children.
Performance of children and adolescents with ADHD and 
with ADHD combined with ODD
We found that four children from the group with ADHD
and ODD had a worse understanding compared with
other children. Therefore, understanding was poorer in
the group of children and adolescents with the ADHD
combined with ODD and their answers were less differen-
tiated compared with the group of patients with ADHD
alone.
Three of these children had either a lower IQ compared
with the total sample or no experience with medication
before entering the study or both. One of the children had
an average IQ and experience with medication. As the
sample size is small and all factors are applicable, none of
these factors can be validated as the essential reason for
the poorer performance in the MacCAT-CR. But it may be
seen as a trend that IQ and experience influence under-
standing and reasoning, whereas a conflicting relation-
ship that is due to externalizing disorders seems to have
no negative influence on willingness to participate.
Discussion
This study revealed that legal minors demonstrated a large
number of competences. Procedures and issues related to
study examinations were very well understood by children
and they also performed very well in appreciating advan-
tages, disadvantages or discomforts caused by study pro-
cedures. But more abstract subjects like the primary
objective of the trial were not well understood and appre-
ciation was low – by both children and adolescents and
often by parents. The capacity to understand the nature of
placebo was low and children and adolescents had an
inadequate appreciation of the probability of receiving
placebo. The study revealed some indications of therapeu-
tic misconceptions in children as well as in parents when
joining the trials.
These results correspond to prior findings which reported
that children and adolescents understand concrete treat-
ment procedures very well [41], but that children below
the age of 12 or 9 years had problems with understanding
and cannot be expected to consent or assent to clinical
research in a meaningful way [19,42]. If children younger
than 12 years have fears about negative consequences if
they ask to stop participating in studies as was reported
[19], then a prerequisite for a meaningful assent or con-
sent is not fulfilled. In our example, children and adoles-
cents really felt free to withdraw from the study and
indicated that they had no worries about any negative
consequences with regard to doctors, which is consistent
with the results obtained by Tait et al. [10,11]. Therefore,
children with a psychiatric disorder also seem to under-
stand one essential element of informed consent, the
autonomy of the decision to join or to quit a trial. Further-
more, they balanced the potential disadvantages, for
instance the expenditure of time on study examinations
against possible advantages, such as once-a-day dosing or
more effective treatment, which indicates meaningful rea-
soning. According to the responses given by our partici-
pants, it is reasonable to conclude that some issues
required by informed consent can also be fulfilled by legal
minors with psychiatric disorders.
But we found that some fears and worries which impacted
on the decision-making of children and adolescents were
not immediately related to study withdrawal with regard
to the informed consent paradigm. The children and ado-
lescents in our group worried about their disorder worsen-
ing, about increased problems in school and poor school
performance, or they were afraid that their behaviour
would get worse if they stopped the study medication. It
appeared that the search for a satisfactory treatment
option made children and adolescents prepared to accept
certain discomforts such as the study procedures. As pae-
diatric psychiatric disorders impair social functioning and
also impact on children's families and social circle, these
more abstract and inter-personal aspects that the children
expressed as motivators for study participation seem to be
particular to child and adolescent psychiatric patients,
who join clinical trials to improve their complex impair-
ment.
The possible adoption of parental wishes was not directly
expressed by children. If children really assumed that their
parents wanted them to join the trial, they did not directly
communicate this in the interview as being an influential
factor in making their decision. But children and adoles-
cents stated that parents feared that their behaviour could
worsen if they did not join the trial. As a consequence, theChild and Adolescent Psychiatry and Mental Health 2009, 3:2 http://www.capmh.com/content/3/1/2
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implication is that children and adolescents feared that
deterioration in their behaviour could cause problems in
their interaction and relationship with their parents. This
may reflect a special kind of "altruistic" motivation in
children for participating in research projects on child and
adolescent psychiatry. But it is reasonable to assume that
the motivation to try a new medication would not change
if the same medication were offered in routine care. There-
fore this "altruistic" motivation on the part of children
would not differ from the general motivation of children
with behavioural problems to undergo any treatment to
improve their behaviour. We did not observe that the
presence of ODD was directly connected with a more neg-
ative attitude in the children towards clinical trials. On the
contrary, fears about the negative consequences of their
disorder even made them prepared to balance discomfort
against the possible benefits of the study medication.
The difficulties we observed in the study that children and
adolescents experience in appreciating complex research
concepts may imply that they need protection if they are
involved in research projects. Parental consent is needed
to protect children, as they remain vulnerable, even
though their factual understanding is good. Otherwise,
the partial competences shown by the legal minors,
whom we observed in the study, should encourage the
development of shared decision making in these issues,
which would guarantee the participation of children and
adolescents in decision making while respecting their free
will [5].
Additionally some parents lacked competences. There
have been previous reports about therapeutic misconcep-
tions held by parents or patients in general if they or their
children were asked to join a trial [9,43]. In these studies,
less extensive information methods were used compared
to our study, but even the application of a very complex
and detailed method like the MacCAT-CR cannot avoid
therapeutic misconceptions by parents or children. We
detected these misconceptions in our study as well: in par-
ticular, the children, in general, did not appreciate that
they would not receive the best proven treatment. Never-
theless, the children reasoned that they were asked to par-
ticipate to test whether this medication worked, so they
understood that there was no guarantee that the study
drugs were effective. The practice of providing informa-
tion to parents, children and adolescents in clinical trials
or studies can be improved by using structured interviews.
This increases understanding, even that of younger chil-
dren. The discrepancy between clinical (all parents and
children were judged to be competent to join the studies)
and formal evaluations (in which doubts are raised
whether all subjects are competent) points to the influ-
ence that the procedure used exerts on competence judge-
ments, and also demonstrates that a more formal
evaluation can help to identify patients who need further
information. As the aim cannot be to obtain informed
consent in a legal meaning from legal minors or young
children, the primary target of clinical investigators in
clinical studies with an ethical position should be to
improve information for minors and not to obtain a "for-
mal" informed consent. Parents should be informed in
precise terms that the primary purpose is research, and
also why this is the primary purpose. Researchers should
be aware of the fact that not all parents understand infor-
mation sufficiently well, and information should stress
the importance of identifying these parents and patients
so as to provide iterative and clear explanations and infor-
mation for them. Using a suitable instrument can help to
detect misconceptions. We would not suggest using the
present form of the MacCAT-CR routinely to obtain con-
sent or assent, but it is a clear strength of the MacCAT-CR
that it reinforces children's and adolescents' reasoning
about their decisions and it provides reassurance about
their comprehension of their decision to take part in a
study, which is an essential part of each "Informed Con-
sent", as well as being essential to the investigator's assess-
ment of the subject's comprehension [30]. Therefore, this
instrument should be further developed and modified for
the use in children and adolescents.
In conclusion, the motivating factors reported by children
in this study demonstrate that further studies are needed
to examine the attitudes of children towards clinical
research and to analyse in more detail and in different
studies what motivates children to take part in clinical tri-
als and whether the severity of their disorder influences
their attitudes and willingness to participate in research
projects.
Limitations
This was a feasibility study and therefore the sample size
was small. Results may be different in studies with chil-
dren and adolescents who have other paediatric and ado-
lescent psychiatric disorders, such as anxiety disorder or
schizophrenia. The clinical trials differed in their study
procedures: one was a randomized trial, but not the other.
One trial included invasive study procedures such as
drawing blood, fasting etc., the other did not.
Conclusion
Even if children and adolescents showed some deficien-
cies in understanding and appreciating the nature of a
clinical trial and its primary objective, these results must
be related to studies with adults, which also found that up
to 60% of adults demonstrated problems in understand-
ing the contents of the information about clinical trials or
seemed unaware that treatment was randomly deter-
mined and different from personalized care [44]. The chil-
dren, adolescents and parents in our study also showedChild and Adolescent Psychiatry and Mental Health 2009, 3:2 http://www.capmh.com/content/3/1/2
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poor performance in appreciating the primary objective
and in understanding the meaning of placebo. Clinical
investigators must be aware of these deficits and miscon-
ceptions and improve information about these issues.
Hopes of an improvement in behavioural symptoms and
of better social functioning motivated both the legal
minors and their parents to assent or consent to study par-
ticipation. IQ and age of the children influenced under-
standing, but basic elements of the "informed consent"
paradigm, such as making the choice freely without nega-
tive consequences for further treatment, were understood
by almost all children. The therapeutic misconceptions we
observed were related to receiving best individualized care
or the hope of being selected to test whether the study
medication worked well in the single, individual case.
Although, in our study, children, adolescents and parents
received information leaflets about the clinical trial prior
to verbal discussions, the problems of understanding
described above still existed. Even if the MacCAT-CR is an
instrument which may improve information about clini-
cal trials in children by structuring the information proc-
ess, additional or alternative methods of information
about the nature and probable consequences of clinical
trials are needed. The MacCAT-CR helps to identify thera-
peutic misconceptions and can also assist in providing
more precise information to these patients with miscon-
ceptions. The results emphasize both the need to protect
children involved in clinical trials by the requirement for
parental consent, and the need for shared decision mak-
ing about participation in clinical trials by children and
parents.
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